HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $746,690 | +25.6% | 19,547 | +18.8% | 0.00% | 0.0% |
Q2 2023 | $594,734 | +25.8% | 16,457 | +32.2% | 0.00% | 0.0% |
Q1 2023 | $472,897 | -74.5% | 12,449 | -61.8% | 0.00% | -75.0% |
Q4 2022 | $1,854,211 | +56.7% | 32,616 | +9.0% | 0.00% | +33.3% |
Q3 2022 | $1,183,000 | -33.3% | 29,924 | -25.7% | 0.00% | -25.0% |
Q2 2022 | $1,774,000 | +216.8% | 40,300 | +185.3% | 0.00% | +300.0% |
Q1 2022 | $560,000 | -10.5% | 14,125 | -9.4% | 0.00% | 0.0% |
Q4 2021 | $626,000 | -41.4% | 15,589 | -40.6% | 0.00% | -50.0% |
Q3 2021 | $1,068,000 | +71.4% | 26,263 | +92.2% | 0.00% | +100.0% |
Q2 2021 | $623,000 | +12.5% | 13,662 | +3.5% | 0.00% | 0.0% |
Q1 2021 | $554,000 | -78.4% | 13,202 | -78.0% | 0.00% | -85.7% |
Q4 2020 | $2,569,000 | +801.4% | 60,125 | +459.1% | 0.01% | +600.0% |
Q3 2020 | $285,000 | -15.2% | 10,754 | -14.4% | 0.00% | 0.0% |
Q2 2020 | $336,000 | +127.0% | 12,557 | +53.2% | 0.00% | 0.0% |
Q1 2020 | $148,000 | – | 8,199 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |